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Cissampelos  sympodialis  Eichler,  Menispermaceae,  is  widely  used  by Indian  tribes  and  folk  medicine  to
treat  various  inﬂammatory  disorders,  including  asthma.  Clinical  toxicological  trials  were  made  with  the
tea of C.  sympodialis,  a  medicinal  plant.  The  study  took  place  at Lauro  Wanderley  Hospital/UFPB-PB,  where
seventeen  healthy  volunteers  were  chosen,  among  those  six  men  and  eleven  women  who  orally  ingested,
during  four  weeks  uninterruptedly,  150 ml of  the  tea, once  a day.  Before  the  ﬁrst  ingestion  and  after  the
last  one,  the  participants  were subjected  to clinical  and laboratorial  tests  for their overall  conditions  inissampelos sympodialis
enispermaceae
ea
order  to analyze  the  toxicity  of  the  plant. The  results  demonstrated  that the  volunteers  neither  experience
clinical  nor  laboratorial  alterations,  as well  as no  signiﬁcant  adverse  effects,  apart  from  little  change
detected  in their  hematological  tests.  Nevertheless,  none  demonstrated  any  pathological  conditions,  just
alterations  of  the  normal  human  being  physiology.  Therefore,  it is concluded  that  these  data  complement
that  obtained  during  pre-clinical  studies  and  conﬁrm  a  low  toxicity  of  this  plant.
©  2015 Sociedade  Brasileira  de  Farmacognosia.  Published  by Elsevier  Editora  Ltda.  All  rights  reserved.ntroduction
The herbal infusion is a drink made from leaves, ﬂowers, seeds,
ruit, stalks and some plant species roots (Zhao et al., 2013; Anvisa,
010). The preparation consists of pouring boiling water over the
erbal drug (Anvisa, 2010).
Herbal products are easily available and widely commercialized
Zhao et al., 2013; Owens et al., 2014), therefore being a way of com-
lementing traditional medicine all over the world (Owens et al.,
014). However, those are not completely free of possible toxicity
r other adverse effects (De Smet, 2004).
The infusion of Cissampelos sympodialis Eichler, Menisperma-
eae, species is widely used by Indian tribes and folk medicine to
reat various inﬂammatory disorders, including asthma (Bezerra-
antos et al., 2004; Costa et al., 2008; Rocha et al., 2010; Marinho
t al., 2012; Cavalcanti et al., 2013; Vieira et al., 2013). Asthma
∗ Corresponding author.
E-mail: liane.franco@ccs.ufpb.br (L.F.B. Mangueira).
http://dx.doi.org/10.1016/j.bjp.2015.06.009
102-695X/© 2015 Sociedade Brasileira de Farmacognosia. Published by Elsevier Editorais a medical condition which presents as main physiopathologi-
cal characteristic bronchial inﬂammation, accompanied by lower
airway hyper responsiveness and variable airﬂow limitation. This
inﬂammation is associated with severe leukocyte recruitment and
their activation at the site of lesion (Bezerra-Santos et al., 2012;
Cavalcanti et al., 2013; Ribeiro-Filho et al., 2013).
The species is endemic in the Northeast and Southeast of
Brazil, frequently occurring in open areas, as shrubs in sandy
soil (Barbosa-Filho et al., 1997). The plant is popularly known as
“milona”, “jarrinha”, “orelha-de-onc¸ a” and “abuteira” (Agra et al.,
2007a,b).
Several studies were conducted with this plant, which have
proved its therapeutic potential (Cavalcanti et al., 2013). Studies
revealed anti-inﬂammatory activity and the potential for modulat-
ing the microbicide activity of macrophages by increasing the IL-10
production along with inhibition of NO synthesis. Furthermore, the
ﬁndings proved the efﬁcacy of C. sympodialis upon the regulation
of B cell function and the immunoglobulin secretion in allergic dis-
eases, as well as autoimmune disease synthesis (Cavalcanti et al.,
2013; Vieira et al., 2013; Piuvezam et al., 2012).
 Ltda. All rights reserved.
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Vieira et al. (2013) demonstrated that the inhalation of C. sym-
odialis in animals with allergic inﬂammation of the airways is as
ffective as the oral treatment with dexamethasone for controlling
he inﬂammatory response in the lungs and the production of IgE.
ltimately, the results suggest that the leaves of C. sympodialis may
e material for a herbal medicine.
In pre-clinical toxicological assays with the AFL (alcoholic frac-
ion of leaves) of C. sympodialis done in rats (male and female),
t was investigated the sub-acute (four weeks) and chronicle (thir-
een weeks) toxicity of the popular administration (9 mg/kg/orally).
hese studies suggested lack of toxicity in these animals. Doses
dministrated 5–225 times higher than the ones ingested by men
videnced, in mice, inﬂammatory processes and an increase of hep-
tic enzymes, besides the hyperplasia of Kupffer cells, reversible
hirty days after the administration of the extract was suspended
Diniz, 2000).
Data published in pre-clinical studies with C. sympodialis leaves
nable clinical assays which may  initially establish the safety and
ubsequently the effectiveness of C. sympodialis in humans. Thus,
his study intended to ascertain the safety of this medicine in poten-
ial. Based on clinical phase 1 parameters in conjunction with the
nes in the pre-clinical studies which have already been published,
here is craving for registering with Anvisa (CNS, 1997; Anvisa,
010).
aterial and methods
lant material
The leaves of Cissampelos sympodialis Eichler, Menispermaceae,
ere collected during the months of March and September of 2012
n the garden of medicinal plants at the Laboratory of Pharmaceu-
ical Technology Prof. Delby Fernandes de Medeiros, Campus I at
ederal University of Paraíba, where the plant has been cultivated.
he identiﬁcation and morphological description of the plant were
ade by Dra. Maria de Fátima Agra. A sample is located in the Lauro
ires Xavier herbarium, at UFPB, by the voucher specimen number
gra 1456 (JPB).
he acquisition of C. sympodialis sachets
The leaves of C. sympodialis were dehydrated in a greenhouse
ith air ﬂowing at 38 ◦C for 72 h and ground in a Harley type
rinder, having the average yields calculated. After the pounding,
he dried leaves were submitted to a phytochemical/quality con-
rol triage, and then sent to the Aplaf Ltda, São Paulo-SP, being this
ompany responsible for producing and ratifying the quality con-
rol of the C. sympodialis sachets. Each unit, produced with ﬁlter
aper for speciﬁc use, contained 1 g of the powder.
hytochemical
A phytochemical trial of C. sympodialis leaves infusion was con-
ucted according to Matos (1997). During the trial, the presence of
lkaloids, steroids, tannins, ﬂavonoids and saponin were detected.
The classes of chemical substances present on the leaves of C.
ympodialis were characterized before the sachets production, thus
eing considered an indispensable stage for their standardization.
earch of warifteine and methylwarifteine alkaloids in teas
achets of C. sympodialisThe teas were prepared under the same conditions of clinical
tudies (one sachet containing 1 g of the powder C. sympodialis was
ubjected to infusion for 15 min). Farmacognosia 25 (2015) 491–498
HPLC equipment and conditions
All solvents used were HPLC level. Deionized Milli Q water
(Millipore, Bedford, MA)  was used to prepare the mobile phase
and diluents solutions. All chromatographic runs were carried
out using a Sykam HPLC System, consisting of a S7131 pump. A
S3240 photodiode-array detector (DAD) was  used for detection.
Full spectra were recorded in the range 200–400 nm.  Equipment
control, data acquisition and integration were performed with Clar-
ity software. Chromatographic separations were achieved using
methodologies based on Aragão (2002) and Marinho (2011). The
mobile phase consisted of a mixture of methanol/CH3CO2H 0.1%
(35:65, v/v). Flow-rate was set to 0.3 ml/min and the injection
volume was 20 l. All experiments were carried out at room tem-
perature. The DAD detected the presence or not of alkaloids peaks
in sachets of C. sympodialis. It was obtained spectrum UV of alka-
loid templates of C. sympodialis (warifteine and methylwarifteine)
within the same conditions proposed by the method and saved on
a data base supported by the Clarity software. The substances were
analyzed through HPLC/UV-DAD and by comparing the time reten-
tion in the extract peaks with the ones collected with authentic
reference standards.
Research ﬁeld
This research took place in Lauro Wanderley University Hospital
at Federal University of Paraíba, where further trials were done in
the clinical analysis laboratory, in the cardiology room as well as
in the ambulatory at CRAS (Reference Server Care Center). Protocol
clinic was  conducted/deﬁned according to the Brazilian resolutions
n◦ 251/97 and 466/12 from the CNS, the international standards
from the World Health Organization 2011 and good clinical practice
(GCP) (CNS, 1997; CNS, 2012).
Volunteers
The clinical study was open and not randomized, performed
with individuals participating voluntarily. The sample consisted of
eighteen volunteers, six men  and eleven women (one quitclaim)
between 23 and 60 years old, were chosen after complete clini-
cal and laboratorial trials which aimed to ascertain proper health
conditions in order to participate in this research.
Experimental protocol
The volunteers had a 150 ml  dose of the herbal product orally,
once a day, using the sachets with leaves of C. sympodialis for four
weeks. Thus, this study was  conducted from May  2012 to June 2013.
After receiving the sachets, the participants were weekly monitored
(0-1-2-3-4 weeks), starting from day 0.
Before the ﬁrst ingestion of the product and a day after the last
one, the participants (men and women) were subjected to a clini-
cal and laboratorial evaluation for their overall conditions. They did
the following tests: glucose, creatinine phosphokinase (CPK), tria-
cylglyceride, total cholesterol and fractions, lactate dehydrogenase
(LDH), amylase, sodium, potassium, aspartate transaminase, ala-
nine transaminase, total bilirubin and fractions, gamma GT, alkaline
phosphatase, total protein and fractions, creatinine, uric acid, urea,
complete blood count, platelet count and urinalysis I. A twelve-lead
electrocardiogram was also done.Throughout the course of the study, the volunteers were
instructed to report to the researchers any signs or symptoms that
might present adverse reaction and were also given a questionnaire
to ﬁll in, if at all.
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xclusion criteria
Individuals who had any clinical or laboratorial alterations –
epatic, renal or cardiac dysfunction; pregnancy; use of alco-
ol and/or any medicines – during the initial clinical tests were
xcluded from this study.
thical aspects
The research project, with the protocol and consent forms, was
ubmitted and approved by the Committee of Ethics in Research
ith humans at Lauro Wanderley University Hospital – UFPB on
5/05/2010 – protocol no. 284/10.
All volunteers were informed about the nature and objectives
f the study and those who agreed to participate gave their formal
ritten consent after signing the Statement of Informed Consent.tatistical analysis
The evaluation of the volunteers’ hematological and biochemical
arameters, which aimed to diagnose whether the participants metpelos sympodialis. Five unknown peaks are eluting: A, B, C, D and E.
the standards for an individual considered healthy, was performed
by comparing the results obtained throughout the treatment and
the ones acquired during the initial trial for each volunteer (basal
time). The ﬁgures were expressed by mean ± standard error of
mean (SEM) of the seventeen participants, separating them by gen-
der, according to the type of test and evaluation period. It was
used the Student’s “t” test for paired samples *p < 0.05 and One-way
ANOVA/Tukey. *p < 0,05. All data were analyzed using the statistical
program Graph Pad Prism ® version 6.02.
Results and discussion
The search for warifteine and methylwariﬁteine in teas prepared
with C. sympodialis sachets were performed through analysis by
High Performance Liquid Chromatography coupled to UV detec-
tor with photodiode array (HPLC/DAD). The HPLC chromatogram,
Fig. 1, in C. sympodialis tea showed ﬁve unknown peaks deﬁned as:
A, B, C, D, E and the absence of warifteine and methylwarifteine in
measurable concentrations. This fact can be explained because pre-
vious studies used ethanolic extraction. This study used hot water
extraction.
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Table 1
Patients’ biochemical parameters, either sex, from the Clinical Trial with infusion of the leaves of Cissampelos sympodialis. Values are expressed in mean ± SEM.
Groups Glucose (mg/dl) Total bilirubin
(mg/dl)
Direct bilirubin
(mg/dl)
Indirect
bilirubin (mg/dl)
Uric acid (mg/dl) Creatinine (mg/dl) Urea (mg/dl)
Men
Reference 70–99 0.2–1.2 0.0–0.5 0.0–0.5 3.5–7.0 0.9–1.3 19.0–44.0
1◦Appointment 89.67 ± 1.76 0.74 ± 0.23 0.21 ± 0.06 0.54 ± 0.17 6.05 ± 0.43 1.03 ± 0.07 29.50 ± 3.15
30  Days 90.33 ± 2.17 0.96 ± 0.34 0.26 ± 0.07 0.70 ± 0.27 6.03 ± 0.49 1.03 ± 0.07 28.33 ± 2.08
Women
Reference 70–99 0.2–1.2 0.0–0.5 0.0–0.5 2.5–6.2 0.6–1.1 14.9–40
1◦Appointment 87.55 ± 1.97 0.63 ± 0.15 0.16 ± 0.03 0.46 ± 0.12 4.23 ± 0.34 0.73 ± 0.03 27.20 ± 2.39
30  Days 90.55 ± 4.10 0.64 ± 0.16 0.18 ± 0.03 0.46 ± 0.13 4.25 ± 0.34 0.76 ± 0.04 26.33 ± 2.84
Student’s “t” test *p < 0.05 probability.
Table 2
Patients’ biochemical parameters, either sex, from the Clinical Trial with infusion of the leaves of Cissampelos sympodialis.
Groups AST (U/l) ALT (U/l) GGT (U/l) Total phosphinic creatine (U/l) LDH (U/l) Amylase (U/l)
Men
Reference 5–34 6–55 12–24 <190 125–243 25–125
1◦Appointment 25.17 ± 3.11 42.50 ± 8.96 47.33 ± 10.67 122.00 ± 18.18 65.80 ± 4.42 79.50 ± 13.71
30  Days 25.17 ± 3.03 47.33 ± 12.65 47.33 ± 14.78 120.00 ± 24.45 186.00 ± 18.51 78.33 ± 13.07
Women
Reference 5–34 6–55 9–36 <167 125–243 25–160
1◦Appointment 21.40 ± 4.10 25.70 ± 6.55 23.90 ± 5.65 97.50 ± 15.99 153.80 ± 4.35 67.30 ± 3.17
30  Days 19.40 ± 2.11 22.40 ± 3.40 22.85 ± 3.51 103.5 ± 11.05 156.00 ± 4.79 73.43 ± 5.07
AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, Gamma-glutamyl transpeptidase; LDH, lactate dehydrogenase.
Values are expressed in mean ± SEM. Student’s “t” test *p < 0.05 probability.
Table 3
Patients’ hematological parameters, either sex, from the Clinical Trial with infusion of the leaves of Cissampelos sympodialis.
Groups RBC (106/mm3) Hemoglobin (g/dl) Hematocrit (%) MCV  (ﬂ3) MCH  (pg) MCHC (%) RDW (%)
Men
Reference 4.5–6.0 12.8–17.8 40–52 82–98 27–33 32–36 11.5–14.5
1◦Appointment 5.33 ± 0.10 15.72 ± 0.46 45.90 ± 0.99 86.13 ± 1.44 29.51 ± 0.91 34.24 ± 0.52 10.63 ± 0.33
30  Days 5.32 ± 0.13 15.76 ± 0.29 46.06 ± 1.01 86.65 ± 1.01 29.68 ± 0.55 34.26 ± 0.33 10.92 ± 0.15
Women
Reference 3.9–5.3 12–15.6 36–48 82–98 27–33 32–36 11.5–14.5
1◦Appointment 4.42 ± 0.09 13.33 ± 0.23 39.02 ± 0.68 88.31 ± 1.19 30.20 ± 0.52 34.17 ± 0.22 11.22 ± 0.34
30  Days 4.38 ± 0.10 13.22 ± 0.23 38.51 ± 0.61 88.07 ± 1.04 30.25 ± 0.61 34.34 ± 0.38 11.38 ± 0.38
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VBC, red blood cells; MCV, mean corpuscular volume; MCH, mean corpuscular hem
idth.
alues  are expressed in mean ± SEM. Student’s “t” test *p < 0.05 probability.
This study investigated the clinical toxicity in seventeen
umans, in search of the safety of this medicine in potential. The
linical phase I concerns the ﬁrst moment when the medicine is
ested in a group of healthy volunteers. This phase seeks to establish
he safety, pharmacokinetic proﬁle and tolerability in a preliminary
ormat of the substance in humans (CNS, 1997; Mesia et al., 2011).
Tests were carried out for urinalysis I, hematological and bio-
hemical parameters of patients, which showed that there was just signiﬁcant change in statistics in four hematological parameters,
n which it was observed a decline in leucocytes and neutrophils
n men, an increase in eosinophils in women and in lymphocytes
n men. Although these changes were statistically signiﬁcant, they
able 4
atients’ hematological parameters, either sex, from the Clinical Trial with infusion of the
Groups Leukocytes (103/mm3) Neutrophils (%) Eosinophil
Men
Reference 4.0–11.0 45–70 1–6 
Basal 9265 ± 718.40  58.83 ± 3.08 2.83 ± 0.60
30  Days 8293 ± 636.10  53.67 ± 2.33 3.00 ± 0.37
Women
Reference 4.0–11.0 45–70 1–6 
Basal 6360 ± 342.50  55.00 ± 1.87 3.00 ± 0.73
30  Days 6579 ± 412.70  56.02 ± 2.81 3.87 ± 0.69
alues are expressed in mean ± SEM. Student “t” test *p < 0.05 probability.n; MCHC, mean corpuscular hemoglobin concentration; RDW, red cell distribution
do not represent a pathological condition, and perhaps are just an
alteration of normal human physiology (Tables 1–4).
The leucocytes and lymphocytes are cells responsible for pro-
tecting the organism against infections. Lymphocytosis is caused
by neoplasia, viral infections such as rubella, mononucleosis, and
mumps; bacterial infections, protozoans, among others (Hoffbrand
and Moss, 2013; Musso et al., 2014). The neutrophils are mainly
responsible for the phagocytes is of cells and extraneous material.
Neutropenia is mainly caused by dysplasia, infections, inﬂamma-
tion, intravascular destruction (immune), drugs and chemicals,
among others (Musso et al., 2014; Spaan et al., 2013). On the other
hand, the eosinophilia is related to allergic responses, parasitic
 leaves of Cissampelos sympodialis.
s (%) Lymphocytes (%) Monocytes (%) Platelet (1/mm3)
20–45 2.0–10.0 150,000–450,000
 30.83 ± 3.12 7.5 ± 0.68 207717 ± 31716
 35.67 ± 2.14 7.5 ± 0.56 237683 ± 23855
20–45 2.0–10.0 150,000–450,000
 34.64 ± 2.16 6.73 ± 0.57 220391 ± 19885
 32.76 ± 3.01 6.49 ± 0.62 224491 ± 15365
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aig. 2. Weekly evaluation of women according to the following parameters: tempe
ass  index. Values are expressed in mean ± SEM. One-way ANOVA/Tukey. *p < 0.05
iseases, acute infection, certain skin diseases, drug sensitivity,
mong others (Chen et al., 2013; Dasgupta et al., 2013; Musso et al.,
014). These pathologies were not detected in the volunteers who
articipated in the study.
Within this context, the low toxicity of C. sympodialis was ver-
ﬁed, since it was not revealed any signiﬁcant statistical changes
n the volunteers’ biochemical tests, despite the fact that studies
emonstrate hepatic alterations in humans throughout continu-
us use of medicinal plants (Paulo et al., 2009; Bunchorntavakul
nd Reddy, 2013). Furthermore, when comparing the results from, respiratory and cardiac frequency, systolic and diastolic blood pressure and body
the pre-clinical trials to the clinical ones, we realized that there may
be some statistical variation, yet only in overdose (Diniz, 2000).
Along the clinical tests, anamnesis, temperature measurement,
blood pressure investigation, respiratory and cardiac frequency,
body mass index and application of questionnaires related to pos-
sible side and adverse effects were conducted by the physician
responsible for the research, who  evaluated and diagnosed that
the individuals involved in the study were in normal standards
(Figs. 2 and 3). The electrocardiograms showed eleven normal ones
before and after ingestion of the product; two  conduction disorders
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ass  index. Values are expressed in mean ± SEM. One-way ANOVA/Tukey. *p < 0.05
f the right bundle branch before and after; one short PR before
nd after; one bradycardic before and after; one normal before
nd one altered ventricular repolarization after; one bradycardic
efore and 1altered ventricular repolarization after. Nevertheless,
ll electrocardiographic tests were as expected based on normal
imits.
The electrocardiogram (ECG) is a simple and low cost test which
rovides data about the myocardium status, perhaps useful inrespiratory and cardiac frequency, systolic and diastolic blood pressure and body
cardiovascular epidemiology, therefore supporting the diagnosis
of the myocardial infarction, ischemia and cardiac hypertrophy,
and yet detecting the risk of future cardiac events (Cardoso et al.,
2002; Ribeiro et al., 2012).However, the normal range of the electrocardiogram is con-
troversial, hence it demands a thorough analysis of variations
considered expected in the ECG of healthy people, and, only after,
some reﬂection on the meaning of the electrocardiograms which
L.F.B. Mangueira et al. / Revista Brasileira de
Table  5
Side effects and adverse reactions described throughout the clinical study.
Effects Numbers Frequency (%)
Fluid retention 1/17 5.88
Decreased muscle aches 2/17 11,76
Hydration of heels 1/17 5.88
Decreased appetite 5/17 29.41
Reduction in candida 1/17 5.88
Decrease tingling 1/17 5.88
Increased intestinal motility 2/17 11.76
Dizziness 1/17 5.88
Somnolence 1/17 5.88
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bronchial asthma in mice with eosinophilic bronchitis. PLOS ONE 8, e75195.
De Smet, P.A., 2004. Health risks of herbal remedies: an update. Clin. Pharmacol.Insomnia 1/17 5.88
re undoubtedly abnormal (Moffa and Sanches, 2001; Hampton,
011).
Sinus rhythm is the only one sustained as normal. In youth,
he space RR is reduced, in other words, the cardiac frequency
s increased during inspiration and it is named respiratory sinus
rrhythmia. When the sinus arrhythmia is intense, it may  simulate
n atrial one (Moffa and Sanches, 2001; Hampton, 2011).
There is no single deﬁnition for a normal cardiac frequency, and
he terms bradycardia and tachycardia ought to be used cautiously.
here is no point at which a high cardiac frequency in sinus rhythm
hould be called sinus tachycardia and no upper limit for sinus
radycardia. However, unexpected high or low rates should be
nvestigated. The possible causes for a sinus rhythm of low cardiac
requency are: good physical condition, hypothyroidism, hypother-
ia, acute myocardial infarction, vasovagal attacks and use of
eta-blockers. The most common causes described as sinus rhythm
f high cardiac frequency is: pain, fear, obesity, acute myocar-
ial infarction, pulmonary embolism, anemia, thyrotoxicosis, use of
eta-adrenergic drugs (Moffa and Sanches, 2001; Hampton, 2011).
hese pathologies were not detected in the volunteers who partic-
pated in the study.
Studies showed that small changes in the ECG may be regarded
s “predictive” for clinical signs of a coronary heart disease, which
s related to cardiovascular mortality (Moffa and Sanches, 2001;
ampton, 2011). Some authors suggest that an abnormality in the
T-T segment is an independent indicator of morbidity and mor-
ality from coronary atherosclerosis (Moffa and Sanches, 2001;
aranowski et al., 2012).
For this reason, the ECG has been widely used to identify individ-
als at risk for isquemic heart diseases, still during asymptomatic
tage. This population, once subjected to preventive and quite
ggressive strategies, may  be beneﬁted.
Throughout the clinical research, some side and adverse effects
ere observed, such as: decreased muscle aches; skin hydration;
ncreased intestinal motility; decreased tingling sensation. More-
ver, dizziness, insomnia, ﬂuid retention, somnolence, reduction
n candida and decreased appetite were also reported as side and
dverse effects (Table 5).
These adverse reactions may  be classiﬁed Type A, referred to as
oxic or side effects, which can be explained by the action mecha-
ism of drugs, being a common and expected reaction and of low
ortality rate (Edwards and Aronson, 2000; Sobrafo, 2011).
The data collected from this study demonstrated that the admin-
stration of C. sympodialis leaves infusion in humans, ingested
uring thirty days, was well tolerated, indicating neither clinical
or laboratorial alterations, nor any signiﬁcant adverse reactions.
hese results complement those obtained in the pre-clinical toxi-
ological studies, suggesting low toxicity, in the dosage and route
f administration tested. With this data, there is craving for regis-
ering this medicine in potential with Anvisa and proceed with the
hase II studies. Farmacognosia 25 (2015) 491–498 497
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